Tech Center 1600 • Art Units: 1658 1699
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18251553 | MATERIALS AND METHODS FOR PROTEIN PROCESSING | Non-Final OA | AMGEN INC. |
| 18199012 | USE OF THE SESTRIN2 FOR THE TREATMENT OF CONTRAST-INDUCED ACUTE KIDNEY INJURY | Non-Final OA | UIF (University Industry Foundation), Yonsei University |
| 18274412 | INHIBITION OF DEGRANULATION OF NEUTROPHIL CELLS IN COVID-19 PATIENTS | Non-Final OA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 18284786 | EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING POST COVID-19 | Non-Final OA | PANTAPHARM AG |
| 18284407 | SELECTED AAV COMPOSITIONS HAVING PREFERRED BRAIN ENRICHMENT | Non-Final OA | Capsida, Inc. |
| 18260672 | SYNTHESIS PROCESS | Non-Final OA | Xellia Pharmaceuticals APS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy